Takeda earns win for its TKI inhibitor in tiny lung cancer group — but GI side effects could be an early red flag
Japanese drugmaker Takeda has made a big push in recent years to build a hand in oncology, particularly in the next-gen cancer space. One …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
